Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
JOB$0.19-0.02(-8.21%)GEE Group Inc. Announces Effective Date of Previously Approved Reverse Stock Split[5:10:00 PM ET]BLNK$0.42+0.03(+8.04%)Blink Charging to Host Third Quarter Conference Call on Thursday, November 5, 2026[5:07:00 PM ET]BTRMF$0.12+0.00(+4.43%)Battery Mineral Resources Corp. Announces Proposed C$17 Million Private Placement[5:05:00 PM ET]ISRJF$0.110.00(0.00%)ReGen III Files Motion to Dismiss Complaint[5:05:00 PM ET]CIFR$8.64+0.16(+1.89%)Cipher Digital Announces Participation in Upcoming Investor and Industry Conferences[5:03:25 PM ET]SEAT$2.33+0.15(+6.65%)Vivid Seats to Report Third Quarter 2026 Financial Results[5:01:00 PM ET]EGO$32.80-1.37(-4.01%)Eldorado Gold Reports Q3 2026 Financial and Operational Results and Updates 2026 Guidance; Skouries and McIlvenna Bay Advancing Toward Commercial Production[5:01:00 PM ET]CTXXF$0.36+0.00(+0.20%)CEMATRIX Announces 2026 Third Quarter Financial Results[5:01:00 PM ET]FRTT$0.57-0.08(-11.70%)Fort Technology Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement[5:00:58 PM ET]AEM$185.00+4.29(+2.37%)AGNICO EAGLE REPORTS THIRD QUARTER 2026 RESULTS - STRONG FREE CASH FLOW GENERATION DRIVEN BY SOLID OPERATIONAL PERFORMANCE; ON TRACK TO ACHIEVE 2026 PRODUCTION AND COST GUIDANCE Agnico Eagle Mines Limited (NYSE: AEM) (TSX: AEM) ("Agnico Eagle" or the "Company") today reported financial and operating results for the third...[5:00:00 PM ET]AGI$29.86-1.32(-4.23%)Alamos Gold Reports Third Quarter 2026 Results[5:00:00 PM ET]

ADIL · NASDAQ

Adial Pharmaceuticals, Inc.

$5.00 +1.18 (+30.89%)

Company overview

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$13.1M
Employees
5
Headquarters
Charlottesville, VA
Website
adialpharma.com
CEO
Cary John Claiborne
Listed
July 27, 2018
P/E
-0.51
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$141
Operating income
-$7.5M
EBITDA
-$7.5M
Net income
-$7.8M
EPS
-$9.78
Total assets
$5.2M
Total debt
$0.00
Earnings yield
-195.60%

Price chart

1.072.664.265.857.44
ADIL 1D NASDAQ O3.72H3.98L3.67C3.71+0.03 (+0.82%)Vol7.36K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis GlobeNewswire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer GlobeNewswire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis GlobeNewswire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Announces Inducement Grant under GlobeNewswire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Stock news Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program Globe News Wire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Stock news Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 49.4% in April Defense World
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Stock news Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 21.7% in March Defense World
ADILAdial Pharmaceuticals, Inc. Stock news Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Drop in Short Interest Defense World
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Stock news Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL) Defense World
ADILAdial Pharmaceuticals, Inc. Press release Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Press release Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement GlobeNewsWire
ADILAdial Pharmaceuticals, Inc. Stock news Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 31.2% Defense World
ADILAdial Pharmaceuticals, Inc. Stock news Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Globe News Wire
See more
FAQ

Questions about Adial Pharmaceuticals, Inc.

What does Adial Pharmaceuticals, Inc. do?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
What is ADIL's market cap?
Adial Pharmaceuticals, Inc. (ADIL) is a listed stock with a live quote. The latest market cap on this page is $13.1M.
Where is Adial Pharmaceuticals, Inc. headquartered?
Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, VA.
How do I get ADIL news from the API?
Call GET /v1/news?tickers=ADIL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ADIL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ADIL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ADIL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs